Salidroside suppresses proliferation and migration in prostate cancer via the PI3K/AKT pathway.


Journal

Cancer biomarkers : section A of Disease markers
ISSN: 1875-8592
Titre abrégé: Cancer Biomark
Pays: Netherlands
ID NLM: 101256509

Informations de publication

Date de publication:
2023
Historique:
medline: 21 11 2023
pubmed: 7 8 2023
entrez: 7 8 2023
Statut: ppublish

Résumé

Prostate cancer (PCa) is one of the most common malignancies in men. PCa is difficult to detect in its early stages, and most patients are diagnosed in the middle to late stages. At present, drug therapy for advanced PCa is still insufficient. Some patients develop drug resistance in the later stage of therapy, which leads to tumor recurrence, metastasis and even treatment failure. Therefore, it is crucial to find new and effective drugs to treat prostate cancer. The aim of this study was to investigate the anti-cancer effect of salidroside, an active ingredient in a traditional Chinese herbal medicine, on PCa. Two human PCa cell lines, PC3 and DU145, were cultured and treated with salidroside. Cell viability and proliferation ability were analyzed through CCK-8 and colony assays, and cell migration ability was detected by Transwell and Scratch assays. RT-PCR and WB were used to detected the expression levels of moleculars related to cell proliferation, apoptosis, migration, and AKT signaling pathway. Forthmore, we performed rescue experiments with agonist to verify the affected signaling pathway. Salidroside inhibited the proliferation, colony formation, and migration of PCa cells. Meanwhile, apoptosis of PCa cells was enhanced. Moreover, salidroside inhibited PI3K/AKT pathway in PCa cells. The treatment of AKT agonist 740Y-P abrogated the inhibitory effect of salidroside on the PI3K/AKT signaling pathway. Our study demonstrated that in PCa cells, salidroside inhibites proliferation and migration and promots apoptosis via inhibiting PI3K/AKT pathway.

Sections du résumé

BACKGROUND BACKGROUND
Prostate cancer (PCa) is one of the most common malignancies in men. PCa is difficult to detect in its early stages, and most patients are diagnosed in the middle to late stages. At present, drug therapy for advanced PCa is still insufficient. Some patients develop drug resistance in the later stage of therapy, which leads to tumor recurrence, metastasis and even treatment failure. Therefore, it is crucial to find new and effective drugs to treat prostate cancer.
OBJECTIVE OBJECTIVE
The aim of this study was to investigate the anti-cancer effect of salidroside, an active ingredient in a traditional Chinese herbal medicine, on PCa.
METHODS METHODS
Two human PCa cell lines, PC3 and DU145, were cultured and treated with salidroside. Cell viability and proliferation ability were analyzed through CCK-8 and colony assays, and cell migration ability was detected by Transwell and Scratch assays. RT-PCR and WB were used to detected the expression levels of moleculars related to cell proliferation, apoptosis, migration, and AKT signaling pathway. Forthmore, we performed rescue experiments with agonist to verify the affected signaling pathway.
RESULTS RESULTS
Salidroside inhibited the proliferation, colony formation, and migration of PCa cells. Meanwhile, apoptosis of PCa cells was enhanced. Moreover, salidroside inhibited PI3K/AKT pathway in PCa cells. The treatment of AKT agonist 740Y-P abrogated the inhibitory effect of salidroside on the PI3K/AKT signaling pathway.
CONCLUSIONS CONCLUSIONS
Our study demonstrated that in PCa cells, salidroside inhibites proliferation and migration and promots apoptosis via inhibiting PI3K/AKT pathway.

Identifiants

pubmed: 37545219
pii: CBM220454
doi: 10.3233/CBM-220454
doi:

Substances chimiques

rhodioloside M983H6N1S9
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

321-332

Auteurs

Ru-Han Liu (RH)

Department of combine traditional Chinese and Western Medicine, Huanggang Central Hospital, Huanggang, Hubei, China.
Department of combine traditional Chinese and Western Medicine, Huanggang Central Hospital, Huanggang, Hubei, China.

Teng-Fei Ma (TF)

Department of Neurology, Huanggang Central Hospital, Huanggang, China.
Huanggang Institute of Translational Medicine, Huanggang, Hubei, China.
Department of combine traditional Chinese and Western Medicine, Huanggang Central Hospital, Huanggang, Hubei, China.

Qin Yang (Q)

Huanggang Institute of Translational Medicine, Huanggang, Hubei, China.
Department of Cardiovascular Surgery, Huanggang Central Hospital, Huanggang, Hubei, China.

Wen-Chang Xiao (WC)

Huanggang Institute of Translational Medicine, Huanggang, Hubei, China.
Department of Cardiovascular Surgery, Huanggang Central Hospital, Huanggang, Hubei, China.

Lu Yin (L)

Huanggang Institute of Translational Medicine, Huanggang, Hubei, China.

Miao Yin (M)

Huanggang Institute of Translational Medicine, Huanggang, Hubei, China.

Jin-Song Zhang (JS)

Department of Urology, Huanggang Central Hospital, Huanggang, China.

Chi-Hua Wang (CH)

Huanggang Disease Control Center, Huanggang, Hubei, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH